title: Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management.
abstract: Growth failure associated with severe primary insulin-like growth factor 1 (IGF-1) deficiency (SPIGFD), a condition defined as basal IGF-1 standard deviation score (SDS) less than or equal to -3 and height SDS less than or equal to -3 in a child with normal or elevated levels of growth hormone, can be successfully treated with the recombinant human IGF-1 mecasermin. In this review, we describe the most safe and effective way to use mecasermin in the treatment of patients with SPIGFD, including how to initiate dosing, key side effects, and how to monitor treatment. Finally, mention of how to reinitiate therapy is made, given the recent drug shortage with mecasermin.
authors.affiliation: BMG: The Endocrine Clinic, P.C., 5659 South Rex Road, Memphis, TN, 38119, USA, jaycohen1a@icloud.com.
authors.forename: Jay
authors.initials: J
authors.lastname: Cohen
authors.forename: Sandra
authors.initials: S
authors.lastname: Blethen
authors.forename: Joyce
authors.initials: J
authors.lastname: Kuntze
authors.forename: Susan L
authors.initials: SL
authors.lastname: Smith
authors.forename: Kathleen G
authors.initials: KG
authors.lastname: Lomax
authors.forename: Puthenpurackal M
authors.initials: PM
authors.lastname: Mathew
mesh_terms: D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives / Q000627:therapeutic use; D006130:Growth Disorders / Q000175:diagnosis* / Q000188:drug therapy*; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis* / Q000188:drug therapy*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000172:deficiency*; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; C065700:myotrophin; D007987:Gonadotropin-Releasing Hormone; D007334:Insulin-Like Growth Factor I